Summary
Eli Lilly and Company's 2011 10-K filing highlights a year of revenue growth driven by key products like Cymbalta and insulin, alongside a notable increase in its Animal Health segment. However, this growth was offset by decreased net income, primarily due to the impact of U.S. healthcare reform, increased operating expenses, and charges related to restructuring and collaborations. The company is facing significant patent expirations for major products like Zyprexa and Cymbalta, which are expected to materially impact future revenues. Lilly is actively managing these challenges by investing heavily in its late-stage pipeline, exploring strategic collaborations, and focusing on emerging markets and its animal health business to drive future growth. The filing also details ongoing legal and regulatory matters, including patent litigation and investigations into marketing practices, which represent potential risks. The company's financial condition remains solid with substantial cash reserves and manageable debt, although it is largely self-insured for product liability claims. Investors should closely monitor the impact of patent expirations, the success of new product development, and the evolving regulatory landscape.
Financial Highlights
54 data points| Revenue | $24.29B |
| Cost of Revenue | $5.07B |
| Gross Profit | $19.22B |
| R&D Expenses | $5.02B |
| SG&A Expenses | $7.88B |
| Interest Expense | $186.00M |
| Net Income | $4.35B |
| EPS (Basic) | $3.90 |
| EPS (Diluted) | $3.90 |
| Shares Outstanding (Basic) | 1.11B |
| Shares Outstanding (Diluted) | 1.11B |
Key Highlights
- 1Revenue increased by 5% to $24.29 billion in 2011, driven by Cymbalta, insulin products, animal health, Alimta, Effient, and Cialis.
- 2Net income decreased by 14% to $4.35 billion, or $3.90 per share, due to increased operating expenses and specific charges, including $408.8 million related to U.S. healthcare reform.
- 3Zyprexa revenue declined by 8% due to patent exclusivity loss in October 2011, with an expected further decline of over $3 billion in 2012.
- 4The company reported robust growth in its Animal Health segment, with sales increasing by 21% to $1.68 billion.
- 5R&D expenses increased by 3% to $5.02 billion, reflecting continued investment in a pipeline of approximately 65 potential new drugs.
- 6Key patent expirations are looming for major products such as Cymbalta (2013) and Humalog (2013), posing a significant risk to future revenue.
- 7The company is actively involved in patent litigation concerning Alimta and Strattera, with potential material impacts on future results.
- 8Eli Lilly reported a strong financial position with $6.90 billion in cash, cash equivalents, and short-term investments at year-end 2011.